BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21573973)

  • 1. Outcome of non-metastatic male breast cancer: 118 patients.
    Arslan UY; Oksüzoğlu B; Ozdemir N; Aksoy S; Alkış N; Gök A; Kaplan MA; Gümüş M; Berk V; Uncu D; Baykara M; Colak D; Uyetürk U; Türker I; Işıkdoğan A
    Med Oncol; 2012 Jun; 29(2):554-60. PubMed ID: 21573973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
    Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
    Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
    Amirifard N; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
    Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
    Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Male breast cancers behave differently in elderly patients.
    Tural D; Selçukbiricik F; Aydoğan F; Beşe N; Yetmen O; Ilvan Ş; Büyükünal E; Serdengeçti S
    Jpn J Clin Oncol; 2013 Jan; 43(1):22-7. PubMed ID: 23159765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
    Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
    Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
    Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
    Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
    Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and survival outcome in cerebral metastatic breast cancer.
    Bachmann C; Schmidt S; Staebler A; Schittenhelm J; Wallwiener D; Grischke EM
    Med Oncol; 2014 Mar; 31(3):862. PubMed ID: 24504842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients.
    Bae SY; Lee SK; Koo MY; Hur SM; Choi MY; Cho DH; Kim S; Choe JH; Lee JE; Kim JH; Kim JS; Nam SJ; Yang JH
    Breast Cancer Res Treat; 2011 Apr; 126(2):471-8. PubMed ID: 21287362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.